Fmr LLC Buys 19,670 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Fmr LLC raised its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 575.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,090 shares of the company’s stock after purchasing an additional 19,670 shares during the period. Fmr LLC owned 0.10% of UroGen Pharma worth $293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of URGN. China Universal Asset Management Co. Ltd. grew its position in shares of UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of UroGen Pharma during the third quarter worth $155,000. SG Americas Securities LLC purchased a new stake in shares of UroGen Pharma during the 3rd quarter valued at $179,000. ProShare Advisors LLC acquired a new stake in shares of UroGen Pharma in the 2nd quarter worth $199,000. Finally, GSA Capital Partners LLP acquired a new position in UroGen Pharma during the 3rd quarter valued at about $249,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Friday, December 6th. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a research report on Wednesday, October 16th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Stock Performance

Shares of NASDAQ URGN opened at $10.64 on Friday. The company has a 50 day simple moving average of $12.05 and a two-hundred day simple moving average of $13.82. The stock has a market cap of $249.55 million, a price-to-earnings ratio of -3.38 and a beta of 1.06. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 12 month low of $10.51 and a 12 month high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the prior year, the firm earned ($0.68) earnings per share. As a group, analysts predict that UroGen Pharma Ltd. will post -3.1 earnings per share for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.